Genesystem Q1 2026: Revenue Surges, Capital Increase Successful, but Losses Continue
Consolidated Q1 2026 revenue 32.9 billion KRW, up 419% from 6.3 billion KRW in Q1 2025
Consolidated operating loss 1.63 billion KRW (narrowed from 2.05 billion KRW loss in Q1 2025)
Completed third-party allotment capital increase (1st: 30 billion KRW, 2nd: 30 billion KRW); H Investment Association became largest shareholder (16.81%)
Cash and cash equivalents increased to 4.35 billion KRW from 1.11 billion KRW at end of 2025 (due to capital increase)
Debt-to-equity ratio improved to 66.5% from 85.8% at end of 2025
Consolidated net loss 1.56 billion KRW (narrowed from 1.94 billion KRW loss in Q1 2025)
R&D expenses 0.56 billion KRW (171.4% of revenue), indicating heavy R&D investment
Subsidiary CareVet continuing losses (net loss of 0.11 billion KRW in Q1 2026)
Recognized impairment loss on intangible assets and goodwill of 5.69 billion KRW in fiscal year 2025 (consolidated)
Holding 222,315 treasury shares (acquired via trust contract in 2024, no change in Q1 2026)
Imposed penalty of 16 million KRW in August 2025 for improper disclosure related to contract termination